OraSure (OSUR) Wins FDA Approval for OraQuick(R) In-Home HIV Test

OraSure Technologies, Inc. (Nasdaq: OSUR) today announced that the U.S. FDA has approved the Company's OraQuick® In-Home HIV Test for sale directly to consumers in the over-the-counter (OTC) market – making it the first and only rapid OTC HIV test approved in the U.S. The OraQuick® In-Home HIV Test can detect antibodies to both HIV-1 and HIV-2 with an oral swab, providing a confidential in-home testing option with results in as little as 20 minutes. It is the first rapid diagnostic test for any infectious disease that has been approved by the FDA for sale over the counter.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Lumen Technologies (LUMN) to cut 7% staff
• OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th
• Greenlane Holdings Inc. (GNLN) Receives Nasdaq Non-compliance Notice